Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770886 | 0.84 | PDK2 (0.47) | PDK2PDK4HTR5AMAPK1LMNA | |
| SCHEMBL24029074 | 0.77 | PDK2 (0.60) | PDK2PDK4MAPK1LMNAALDH1A1 | |
| SCHEMBL10311219 | 0.77 | PDK2 (0.60) | PDK2PDK4MAPK1LMNAALDH1A1 | |
| SCHEMBL844744 | 0.75 | PDK2 (0.57) | PDK2PDK4HTR5ALMNAKMT2A | |
| SCHEMBL30242138 | 0.75 | PDK2 (0.57) | PDK2PDK4HTR5ALMNAKMT2A | |
| SCHEMBL8135159 | 0.69 | PDK2 (0.34) | PDK2PDK4HTR5AMAPK1LMNA | |
| SCHEMBL14691238 | 0.69 | PDK2 (0.43) | PDK2PDK4HTR5AMAPK1LMNA | |
| SCHEMBL12165439 | 0.67 | KMT2A (0.44) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL12165443 | 0.67 | KMT2A (0.44) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL10268887 | 0.67 | PDK2 (0.38) | PDK2PDK4HTR5AKMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | PDK2 1714/4885PDK4 2777/4885HTR5A 4019/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | PDK2 1707/4885PDK4 2983/4885HTR5A 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.